Table 1.
Baseline clinical characteristics according to high and low expressions of CLDN-3 and CLDN-4.
| Variables | Total (n = 53) |
CLDN-3 Low (n = 38) |
CLDN-3 High (n = 15) |
p-Value | CLDN-4 Low (n = 16) |
CLDN-4 High (n = 37) |
p-Value |
|---|---|---|---|---|---|---|---|
| Male:female (n) | 31:22 | 24:14 | 7:8 | 0.272 | 7:9 | 24:13 | 0.152 |
| Age (age, ±SD) | 64.1 ± 11.7 | 64.2 ± 11.3 | 65.5 ± 13.0 | 0.183 | 59.2 ± 11.2 | 66.9 ± 11.2 | 0.031 |
| Tumor location (%, n) | 0.018 | 0.397 | |||||
| Upper third | 7.5 (4) | 10.5 (4) | 0 (0) | 0.191 | 0 (0) | 10.8 (4) | 0.171 |
| Middle third | 49.1 (26) | 57.9 (22) | 26.7 (4) | 0.041 | 62.5 (10) | 43.2 (16) | 0.198 |
| Lower third | 43.4 (23) | 31.6 (12) | 73.4 (11) | 0.006 | 37.5 (6) | 49.1 (17) | 0.569 |
| Tumor size (cm, ±SD) | 4.0 ± 2.2 | 3.8 ± 2.2 | 4.7 ± 2.3 | 0.183 | 3.4 ± 1.8 | 4.4 ± 2.4 | 0.111 |
| Synchronous tumor (%, n) | 22.6 (12) | 21.1 (8) | 26.7 (4) | 0.660 | 0 (0) | 32.4 (12) | 0.010 |
CLDN, claudin; SD, standard deviation.